Anakinra and Tocilizumab Enhance Survival and Function of Human Islets During Culture: Implications for Clinical Islet Transplantation
2014 (English)In: Cell Transplantation, ISSN 0963-6897, E-ISSN 1555-3892, Vol. 23, no 10, 1199-1211 p.Article in journal (Refereed) Published
Pretreatment culture before islet transplantation represents a window of opportunity to ameliorate the pro-inflammatory profile expressed by human beta-cells in duress. Analcinra (IL-1 receptor antagonist) and tocilizumab (monoclonal IL-6 receptor antibody) are two known anti-inflammatory agents successfully used in the treatment of inflammatory states like rheumatoid arthritis. Both compounds have also been shown to reduce blood glucose and glycosylated hemoglobin in diabetic patients. We therefore sought to evaluate the impact of anakinra and tocilizumab on human p-cells. The islets were precultured with or without anakinra or tocilizumab and then transplanted in a marginal mass model using human islets in immunodeficient mice. Islet viability was evaluated in an in vitro model. The pretreatment culture led to a significantly improved engraftment in treated islets compared to the vehicle. Anakinra and tocilizumab are not toxic to human islets and significantly reduce markers of inflammation and cell death. These results strongly support a pretreatment culture with anakinra and tocilizumab prior to human islet transplantation.
Place, publisher, year, edition, pages
2014. Vol. 23, no 10, 1199-1211 p.
Anakinra, Tocilizumab, Islet, Transplantation, Culture
Cell and Molecular Biology Immunology in the medical area
IdentifiersURN: urn:nbn:se:uu:diva-237638DOI: 10.3727/096368913X667529ISI: 000343381500003OAI: oai:DiVA.org:uu-237638DiVA: diva2:768603